✨
AI Summary
- Trump's 100% tariffs on some drugs and APIs create uncertainty.
- US tariffs cast a shadow over Chinese drugs approved in the US.
- Key deals include Gilead's Tubulis acquisition and Neurocrine's Soleno bid.